Dihydralazine

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	C02DB01 (WHO)
Identifiers
IUPAC name 4-Hydrazinyl-1-hydrazinylidene-1,2-dihydrophthalazine
CAS Number	484-23-1 N
PubChem CID	10230
ChemSpider	9813 Y
UNII	PCU411F5L6
KEGG	D07170 Y
ChEMBL	ChEMBL35505 Y
CompTox Dashboard (EPA)	DTXSID0022935
ECHA InfoCard	100.006.914
Chemical and physical data
Formula	C8H10N6
Molar mass	190.210 g·mol−1
3D model (JSmol)	Interactive image
SMILES NNc1c2ccccc2C(=NN)Nn1
InChI InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14) Y Key:VQKLRVZQQYVIJW-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Dihydralazine is a prescription drug^[1] with antihypertensive properties.^[2] It functions by combating the effects of adrenaline, and by expanding the blood vessels so as to enable smoother flow of blood by decreasing the pressure. It is generally administered orally, and is available in the form of tablets.^[1] It belongs to the hydrazinophthalazine chemical class.^[3] It has very similar effects to hydralazine.^[3]

Side Effects

• Headache^[1]
• Loss of Appetite^[1]
• Nausea^[1]
• Vomiting^[1]
• Diarrhea^[1]
• Palpitations^[1]
• Increased Heart Rate^[1]
• Angina Pectoris^[1]

Contraindications

Contraindications to this drug include allergic reactions to this drug or to any of its components, ischemic heart diseases, coronary artery diseases, valvular stenosis, aortic aneurysms and pericarditis. Patients who have a previous medical history of kidney dysfunctions, liver damage, heart disorders and cerebro-vascular disorders must exercise caution while taking this medicine. Dihydralazine must not be prescribed to patients who are elderly, and to breastfeeding women. Caution must be exercised while prescribing this medicine to pregnant women.^[1]

Other Important information on intake

When ending intake, you are recommended to withdraw gradually from this medicine, as opposed to abruptly ceasing its intake. Heartbeat problems and edema may occur as adverse effects.^[1]